A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could ...
An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as ...
A phase 1 clinical trial co-led by researchers at Washington University School of Medicine in St. Louis found that a new type ...
In this video, Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, discussed research on the use of ...
Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received 510(k) clearance from the United States Food and Drug ...
A new type of cell-based immunotherapy shows promise for B-cell lymphomas and — due to innovations in manufacturing — could make future cellular ...
Roche (RHHBY) said Monday that it has received 510(k) clearance from the U.S. Food and Drug Administration for its highly-sensitive ...
On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to ...
Bristol Myers Squibb Canada (BMS) is pleased to announce Health Canada's approval of Breyanzi® (lisocabtagene maraleucel), a type of chimeric antigen receptor T cell (CAR T) therapy, for the treatment ...
News Medical on MSN1d
Off-the-Shelf Immunotherapy Approach Shows Promise for B-Cell LymphomaA new type of off-the-shelf cell-based immunotherapy shows promise for B-cell lymphomas, and could make make future cellular ...
While the trial was not designed to evaluate efficacy, Ghobadi and colleagues said that responses were observed across B-cell lymphoma histologies among those treated with the combination ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback